Roxyfoli AM Tablet contains Roxithromycin 150mg + Ambroxol 60mg, a combination therapy designed to treat respiratory bacterial infections while improving mucus clearance. It helps relieve cough, congestion, and infection symptoms efficiently.
Roxithromycin acts as a macrolide antibiotic, inhibiting bacterial protein synthesis, while Ambroxol works as a mucolytic agent, thinning and clearing bronchial secretions for easier breathing.
Tablet formulation ensures accurate dosing, improved patient adherence, and rapid symptom relief. Its dual-action mechanism makes it a high-demand product in hospitals, clinics, and respiratory care pharmacies.
Adding Roxyfoli AM Tablet to your anti-infective and respiratory care portfolio strengthens your offerings with a clinically trusted, fast-moving therapy. Its prescriber acceptance, institutional use, and export potential make it ideal for PCD pharma companies, distributors, and third-party manufacturing partners.